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Abstract
Tuberculosis (TB) of the central nervous system (CNS) is a deadly disease characterized by extensive tissue
destruction, driven by molecules such as Matrix Metalloproteinase-2 (MMP-2) which targets CNS-specific substrates.
In a simplified cellular model of CNS TB, we demonstrated that conditioned medium from Mycobacterium
tuberculosis-infected primary human monocytes (CoMTb), but not direct infection, unexpectedly down-regulates
constitutive microglial MMP-2 gene expression and secretion by 72.8% at 24 hours, sustained up to 96 hours (P <
0.01), dependent upon TNF-a. In human CNS TB brain biopsies but not controls the p38 pathway was activated in
microglia/macrophages. Inhibition of the p38 MAP kinase pathway resulted in a 228% increase in MMP-2 secretion
(P < 0.01). In contrast ERK MAP kinase inhibition further decreased MMP-2 secretion by 76.6% (P < 0.05). Inhibition
of the NFB pathway resulted in 301% higher MMP-2 secretion than CoMTb alone (P < 0.01). Caspase 8 restored
MMP-2 secretion to basal levels. However, this caspase-dependent regulation of MMP-2 was independent of p38
and NFB pathways; p38 phosphorylation was increased and p50/p65 NFB nuclear trafficking unaffected by
caspase 8 inhibition. In summary, suppression of microglial MMP-2 secretion by M.tb-infected monocyte-dependent
networks paradoxically involves the pro-inflammatory mediators TNF-a, p38 MAP kinase and NFB in addition to a
novel caspase 8-dependent pathway.
Background
Central nervous system (CNS) tuberculosis (TB) is heav-
ily over represented in mortality figures causing over
30% of adult TB deaths [1,2]. This is because the
marked CNS inflammatory response to the pathogen is
poorly tolerated. CNS TB is an encephalomyelitis with
invasion of parenchymal brain tissue. The mechanisms
resulting in CNS invasion and tissue destruction are
poorly defined but are known to involve pathogen-dri-
ven host-derived factors [3,4].
Matrix metalloproteinases (MMPs) are a family of 23
zinc containing endopeptidases that degrade extracellu-
lar matrix, facilitate leukocyte recruitment, process
cytokines and chemokines, as well as cleave cell surface
molecules leading to intracellular signaling events [5].
MMP activity is controlled at the transcriptional level
and by tissue inhibitors of metalloproteinase (TIMP-1 to
-4), as well as by compartmentalization and secretion of
pro-forms (zymogens). MMPs have a pivotal role in dis-
eases with marked inflammatory phenotypes such as
rheumatoid arthritis [6], sarcoidosis [7] and athero-
sclerosis [8] as well as CNS disorders like multiple
sclerosis [9] and HIV encephalitis [10]. There is growing
evidence on their role in the pathogenesis of TB
[11-14]. An emerging concept is that important balances
exist, not only between MMPs and TIMPs, but also
between different MMPs with similar substrate affinity
meaning that changes in MMP concentrations may be
an important regulatory mechanism [15,16].
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Control of gene regulation by binding of transcription
factors such as NFB is key in control of specific
MMPs. Most MMPs (e.g. MMP-1, -3, -7, -8, -9, -11,
-12, -13, -19 and -26) have a TATA box at -30 bp from
the transcriptional start site. However, MMP-2, -14 and
-28 lack the TATA box often resulting in high levels of
constitutive expression [17-19]. Steroids, which are tran-
scriptional regulators of MMP gene expression, have a
clinically proven beneficial effect in CNS TB which we
have shown may be due in part to their influence on
MMP secretion [20,21]. Additionally, upstream signaling
molecules including the p38 mitogen activated protein
kinases (MAPK) regulate both MMP gene transcription
and post-transcriptional gene stability [22,23]. Proteoly-
tic cleavage of these kinases and signal transducers by
caspases is usually an inactivation step during apoptosis.
However, some kinases such as MEK kinase-1 are acti-
vated by caspase-3 mediated cleavage [24]. There are
few published data on the control of MMP secretion by
caspases although caspase 8 has been reported to phos-
phorylate STAT1 and thus regulate IFN-g suppression
of MMP-9 secretion [25]. Additionally caspases may
induce apoptosis via an MMP-3 dependent process [26].
MMP-2 degrades basement membrane, type IV col-
lagen, gelatin, aggrecan and laminin [27]. Nonsense
mutations in the human MMP-2 gene result in phenoty-
pic changes defined clinically as the Torg, Winchester
and Nodulosis-Arthropathy-Osteolysis syndromes [28].
MMP-2 is constitutively expressed at high levels by many
cells and is regulated by pro-peptide activation [12,18]. In
the CNS, MMP-2 drives neuronal apoptosis and break-
down of CNS specific substrates such as dystroglycan, a
transmembrane receptor involved in anchoring of astro-
cyte endfeet to the basement membrane via laminin
binding [29]. However, substrate overlap exists as dystro-
glycan is also cleaved by MMP-9 with Mmp2Mmp9 null
mice protected from neuroinflammation in an EAE
model [29]. Cellular influx into areas of inflammation is
regulated by MMP-2 activity. For example, HIV infected
microglia/macrophages secreted proMMP-2 which is
activated by neuronal MMP-14 and cleaves astrocyte-
derived CXCL12 (SDF-1) that is itself neurotoxic and
HIV-infected leucocytes up-regulate MMP-2 (and -9)
secretion in order to cross the blood brain barrier (BBB)
[10,30]. MMP-2 is thus an effector of tissue destruction
in the CNS and mechanisms that lead to its suppression
may be neuroprotective.
There are few published data on MMP-2 in TB but
we and others have shown that cerebrospinal fluid con-
centrations are raised in TBM with no concomitant rise
in TIMP-1 or -2 [21,31,32]. In addition, MMP-2 has
been detected by immunohistochemistry in meninges of
CNS TB patients [31]. In CNS TB excess MMP-2 is
likely to be secreted by microglial cells, the resident
innate cells of the CNS, as TB infected monocytes/
macrophages do not secrete MMP-2 and astrocytes do
not alter MMP-2 secretion in response to TB infection
[11,12]. Therefore we investigated mechanisms regulat-
ing MMP-2 gene expression and secretion in a simpli-
fied cellular model of CNS TB.
Methods
Chemicals for microglial inhibition, including the cas-
pase 8 inhibitor (z-IETD-fmk) were from Sigma-Aldrich
(Gillingham, UK), tissue culture materials from Invitro-
gen (Paisley, UK) and tissue culture plastic from TPP
(Trasadingen, Switzerland) unless otherwise stated.
Anti-TNF-a neutralizing antibodies, recombinant TNF-
a, IL-1Ra, recombinant IL-1b were from Peprotech
(Rocky Hill, NJ, US). SB203580, PD98059, SP600125
and SC-514 were purchased from Calbiochem (Merck,
Nottingham, UK), helenalin from Biomol (Exeter, UK).
M.tb culture and colony counting
The virulent M.tb strain H37Rv Pasteur was cultured
from frozen stocks in Middlebrook 7H9 broth with 10%
OADC enrichment medium (BD Biosciences, Oxford,
UK), 0.2% glycerol, and 0.02% Tween 80 in a shaking
incubator. An optical densitometer (Biowave Cell Den-
sity Meter, WPA, Cambridge, UK) was used to assess
growth of M.tb. Experiments were performed with cul-
tures having an OD of 0.6 after 30 seconds sonication.
The endotoxin level was <0.03 ng/ml LPS as measured
by amoebocyte lysate assay (Associates of Cape Cod,
East Falmouth, MA, US). Multiplicity of infection (MOI)
used in each experiment was checked by colony counts
on Middlebrook 7H11 agar containing ADC enrichment
medium (BD Biosciences) and amphotericin 2.5 μg/ml.
Tb medium was generated by centrifuging M.tb at OD
0.6 at 11,700 RCF (13,000 RPM) for 5 minutes and then
sterile filtering the supernatant through an Anopore 0.2
mM membrane (Anopore, Brentford, UK).
Monocyte isolation and M.tb infection
PBMCs were isolated from single healthy blood donor
residual buffy coats (UK Blood Transfusion Service)
using Ficoll-Paque (GE Healthcare, Little Chalfont, UK)
density gradient centrifugation and a standard adherence
protocol [11]. Monocytes were stimulated by M.tb at an
MOI of 1 or 7H9 medium alone. At 24 hours, cell cul-
ture medium was collected and filtered via a 0.2-μm
pore size sterile filter (Anopore) to remove infectious
particles. This conditioned medium from M.tb infected
monocytes was termed CoMTb and conditioned med-
ium from uninfected, control monocytes termed CoM-
Cont. Similarly CoACont and CoATb were produced
from infecting primary human astrocytes with M.tb but
at MOI of 10 in serum free Modified Eagle’s Medium
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(MEM) after preliminary experiments showed no effect
of an MOI of 1 (data not shown) and no excess cell
death with an MOI of 10.
Human CHME3 microglial cells (a gift of Professor
Marc Tardieu, Paris, France and donated by Dr Nicola
Woodroofe, Sheffield Hallam University, UK) were
maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% FCS (Biosera, Ring-
mer, UK) and 3 mM glutamine in a humidified incuba-
tor with 5% CO2 at 37°C. For experiments cells were
seeded the day previously at 35-50,000 cells/cm2 (to
ensure that MOI was little affected by replication as pre-
vious data confirmed no change in infectivity [33]) and
performed in macrophage serum free medium (MSFM).
Cell culture medium was not replaced and harvested at
specified time points, centrifuged for 5 minutes at
12,000 g to remove cellular debris and samples frozen at
-20°C for later analysis. In direct infection experiments,
M.tb was removed by filtration of all samples through a
0.2-μm pore size Durapore sterile filter (Millipore, Wat-
ford, UK) to remove infectious particles but retain
MMP activity [34].
Gelatin zymography
Zymography is substrate based SDS-PAGE electrophor-
esis which provides data on all the potentially active
MMP present in the sample analyzed [35]. Enzyme
activity is seen as white bands on Comassie blue stained
gels [36]. A 0.2 ng MMP-9 standard (Oncogene, CA,
US) was run on each gel to compensate for gel to gel
variability and gels run as previously described [37].
Gels were analyzed densitometrically by digital image
capture (UVP Transilluminator, Cambridge, UK) and by
Scion Image Analysis software (NIH Image version 1.61,
Bethesda, MD, US).
Analysis of MMP-2 by Luminex multianalyte technology
Total immunoreactive MMP-2 concentrations (pro-,
active and degraded) were analyzed for MMP-2 secre-
tion using Fluorokine multianalyte profiling kits (R&D
Systems, Abingdon, UK) and the Luminex platform Bio-
Plex 200 system (Bio-Rad, Watford, UK). Bio-Plex man-
ager software (version 5.0) was used to construct stan-
dard curves and calculate unknowns. The minimum
level of detection for MMP-2 was 80 pg/ml.
Gene expression analysis by real time quantitative PCR
Microglia were lysed with TRI Reagent and total RNA
was extracted using a standard chloroform-phenol-iso-
propanol protocol using phase-lock-gel tubes (Eppen-
dorf, Cambridge, UK) [38]. RNA was further purified by
a DNAse step using a commercial kit (Ambio, Austin
TX, US). Reverse transcription of 1 μg RNA was fol-
lowed by quantitative polymerase chain reactions
(qPCRs) performed in a 25 μL reaction with a Strata-
gene Mx3000P machine (Stratagene, La Jolla, CA, US)
using 5 ng cDNA, Brilliant II qPCR mastermix (Strata-
gene) and MMP primers and probes as described pre-
viously [39]. The cycle threshold (CT) at which
amplification entered the exponential phase was deter-
mined and this number was used to indicate the amount
of target RNA in each sample. The MMP CT calculated
was also normalized to ribosomal 18s CT run
concurrently.
Western Blotting
Standard western blotting was performed. For p38 MAP
kinase analysis cells were lysed using 200 μl of SDS
sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% gly-
cerol, 50 mM DTT and 0.01% bromophenol blue) and
immediately frozen at -80°C. 40 μl aliquots were run as
described [40]. Overnight incubation in 1:1000 rabbit
primary antibodies to both phosphorylated and unpho-
sphorylated variants of p38 was followed by washing
and incubation with 1:2000 dilution of anti-rabbit HRP-
linked secondary antibody (both Cell Signaling Technol-
ogy, MA, US). Bands were visualized by chemilumines-
cence with the ECL plus system (GE Healthcare)
according to manufacturer’s instructions. Anti-caspase 8
p18 subunit rabbit polyclonal primary antibody (Santa
Cruz, CA, US) was used at 1:1000 dilution with the
same secondary outlined above.
Immunohistochemistry
Ethical consent for the study of anonymized paraffin
embedded sections from the histopathology archive was
obtained from the Hammersmith Hospitals Research
Ethics Committee in accordance with The Human Tis-
sue Act 2004. Formalin-fixed and paraffin embedded
brain biopsies from five immunocompetent patients
with biopsy-proven CNS M.tb infection, two negative
controls (the superior frontal and the superior temporal
gyri of normal post-mortem brains with no pathological
changes) and two positive controls (patients who had
undergone temporal lobectomy epilepsy surgery) were
immunostained for the microglial marker Iba1 (rabbit
polyclonal antibody, Wako, Osaka, Japan, dilution 1:400)
and phospho-p38 (mouse monoclonal, Sigma-Aldrich,
dilution 1:200) as well as standard H&E staining. Five
μm sections were deparaffinised in xylene and rehy-
drated in alcohol. Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide in PBS for 30
minutes and antigen retrieval of sections was performed
by steaming the sections in citrate buffer (0.01 M citrate
pH 6.5) for 30 minutes. Sections were then incubated
with 10% normal goat serum (Vector Laboratories, Bur-
linghame, CA, US) for 20 minutes at room temperature.
The primary antibody was applied overnight at 4°C. The
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following day staining was visualized using biotinylated
secondary antibodies followed by avidin-biotin peroxi-
dase complex (Vectastain Elite ABC kit, Vector Labora-
tories, Burlingham, CA, US). The reaction product was
revealed with 2 μg/mL 3, 3’-Diaminobenzidine (DAB)
and 0.0075% hydrogen peroxide in PBS. Slides were
counterstained with hematoxylin and coverslipped.
Methodological negative controls included omission of
the primary antibody.
Preparation of nuclear & cytoplasmic extracts
30 minute timepoint nuclear and cytoplasmic extracts
were prepared using a commercial kit (Active Motif,
Rixensart, Belgium) according to the manufacturer’s
instructions. To ensure equal total protein loading of
samples between wells in subsequent Western and
ELISA assays of cell lysates a Bradford assay was used to
calculate total protein concentration in samples.
Detection of nuclear NFB DNA binding
To investigate activation of NFB subunits a specific
transcription factor assay (TransAM, Active Motif) with
primary antibodies to p50 and p65 was used. Competi-
tion experiments demonstrated specificity of binding by
adding 20 pM/well of either wildtype or mutated NFB
oligonucleotide before assaying with the p65 antibody
and demonstrating loss of binding with wildtype but not
mutated construct. Values are expressed as fold change
normalized to control conditions.
Results
Microglial MMP-2 secretion is suppressed more by
CoMTb than by direct infection
Microglia were stimulated with 1:5 diluted CoMCont,
CoMTb or infected with M.tb at MOIs of 0.1, 1 and 10.
CoMTb caused a 72.8% suppression of MMP-2 secre-
tion (Figure 1A, P < 0.01). There was a 31% decrease in
MMP-2 secretion due to direct infection of microglia at
an MOI of 10 compared to control (P < 0.01), an infec-
tious load-dependent effect but no effect on cell viability
was demonstrated. CoMTb suppression of MMP-2 was
evident by 24 hours, significant by 72 hours and sus-
tained over 96 hours (Figure 1B). CoMTb decreased
MMP-2 mRNA accumulation by 50% at 24 hours (Fig-
ure 1C, P < 0.05). This effect of CoMTb on microglia
was specific since conditioned media from M.tb infected
primary human astrocytes (CoATb, Figure 1D) had little
effect and microglia (data not shown) had no effect on
MMP-2 secretion.
TNF-a but not IL-1b in CoMTb suppresses microglial
MMP-2 secretion
The effect of pre-incubation of CoMTb for two hours
with increasing concentrations of TNF-a neutralizing
antibody before stimulating microglia was investigated
(Figure 2A). Previously we have demonstrated that a
matched isotype control antibody has no inhibitory
activity [41]. MMP-2 secretion was restored in a dose-
dependent manner. 100 ng/ml recombinant TNF-a sup-
pressed MMP-2 secretion by 61.0% similar to the level
observed with CoMTb (Figure 2B). As we have shown
that the TNF-a concentration in 1:5 CoMTb is approxi-
mately 2 ng/ml [33,37] the data show that TNF-a is
necessary, but not sufficient, to cause CoMTb-induced
MMP-2 suppression. Next, we investigated IL-1b which
is present in CoMTb and important in CNS TB patho-
genesis [20]. Pre-incubating microglial cells with the
inhibitor IL-1Ra or stimulation with recombinant IL-1b
did not alter MMP-2 secretion (Figure 2C &2D). There
was neither an additive nor synergistic effect of adding
these two recombinant cytokines concurrently (Addi-
tional file 1A). Soluble factors derived from M.tb culture
(Tb medium) did not synergize with TNF-a to further
suppress MMP-2 secretion since we demonstrated that
there was no additional effect of adding filtered superna-
tant from cultured M. tuberculosis to TNF-a (Additional
file 1B). Dexamethasone also did not regulate MMP-2
secretion (Additional file 2) nor did addition of IL-6,
Oncostatin M or inhibition of G-protein coupled signal-
ing via pertussis blockade experiments (data not shown).
p38 and ERK MAPK divergently regulate CoMTb-mediated
MMP-2 secretion
Inhibition of the p38 pathway abrogated CoMTb-
mediated MMP-2 suppression (Figure 3). 1 μM
SB230580 caused CoMTb-driven MMP-2 secretion to
return to the same level as constitutively secreted and
10 μM SB230580 caused a 228% increase in MMP-2
secretion over CoMCont (P < 0.01). In contrast ERK
inhibition at 1 μM PD98059 caused a 6.1% decrease in
MMP-2 secretion over and above the 31.2% reduction
due to CoMTb (P < 0.05). 10 μM PD98059 caused a sig-
nificant 76.6% decrease in MMP-2 secretion compared
to CoMCont (P < 0.01). JNK inhibition with 1 μM
SP600125 led to a small but non-significant further
decrease in MMP-2 secretion but 10 μM caused cell
death (data not shown).
Since p38 appeared to have a potentially key role in
CoMTb-induced MMP-2 suppression, the expression of
microglial phospho-p38 in five CNS TB brain biopsies
was investigated for the first time in human brain sec-
tions. Microglial cells appeared to be immunoreactive
for phosphorylated p38 (Figure 4). Specifically nuclei
were more immunoreactive for phosphorylated p38 than
cytoplasm. Negative control brains and relevant metho-
dological negative controls, including omission of pri-
mary antibody, did not demonstrate any p38
immunoreactivity further strengthening these novel data.
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Figure 1 MMP-2 secretion and gene expression is suppressed by CoMTb. (A), Microglial cells were stimulated with control medium (open
bars), CoMCont (diagonal hatched bars), CoMTb (solid bars) or infected with M.tb (grey bars) at an MOI of 1-10. 72 h supernatants were
analyzed by Luminex with a representative gelatin zymogram shown. (B), Kinetics of CoM stimulated MMP-2 secretion analyzed by Luminex
(representative zymogram shown). (C), MMP-2 gene expression is suppressed by CoMTb. mRNA from microglia stimulated for 24 h was analyzed
by RT-PCR, normalized to 18S RNA and expressed as fold change relative to 24 h CoMCont mRNA. The mean ± SD from 3 experiments are
shown analyzed by Student’s t-test. (D), Astrocyte-microglial signaling networks do not suppress MMP-2 secretion. Conditioned medium from
primary human astrocytes was prepared from control (CoACont) and M.tb infected cells (CoATb) and used to stimulate microglia. 72 h cell
culture medium MMP-2 secretion was analyzed by Luminex (representative zymogram shown). A, B & D, Bars represent mean values ± SD of 3
samples, representative of at least duplicate experiments performed in triplicate. Data were analyzed by one-way analysis of variance, followed
by Tukey’s multiple comparison. *p < 0.05, **p < 0.01.
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Figure 2 Suppression of MMP-2 by CoMTb is mediated by TNF-a. (A), CoMTb was preincubated with increasing doses of anti-TNF-a Ab for
2 h. (B), TNF-a suppresses MMP-2 secretion. Cells were stimulated with rhTNF-a 1-100 ng/ml. Note representative gelatin zymogram has been
cut to correspond to the adjacent graph (thick black line). (C), IL-1b does not contribute to CoMTb induced MMP-2 secretion. Cells were
preincubated with IL-1Ra for 2 h. Inhibition of IL-1b activity did not affect MMP-2 secretion. (D), IL-1b alone does not suppress MMP-2 secretion.
Microglial cells were stimulated with rhIL-1b at concentrations of 1-100 ng/ml. Densitometric analysis of gelatin zymography is shown with a
representative gelatin zymogram for A-D. For all experiments bars represent mean values ± SD of three samples, representative of at least
duplicate experiments performed in triplicate. Data were analyzed by one-way analysis of variance followed by Tukey’s multiple comparison. *p
< 0.05, **p < 0.01.
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NFB signalling suppresses MMP-2 gene expression
Since NFB is a key regulator of many MMPs, the effect
of p65 blockade was investigated. Helenalin restored
MMP-2 secretion to basal levels (Figure 5A). Confirma-
tion of these data was obtained by inhibition of IKK2
with SC-514 which resulted in similar dose-dependent
loss of CoMTb mediated MMP-2 suppression (Figure
5B). 5 μM SC-514 resulted in MMP-2 concentrations
that were 157% higher than CoMCont and 301% higher
than CoMTb (both P < 0.01). No such increased secre-
tion was observed with helenalin since this compound
was toxic to cells at concentrations greater than 1 μM.
Caspase 8 inhibition restores CoMTb-induced MMP-2
secretion to control concentrations
We next studied caspase-8 which has been proposed to
have a non-apoptotic role in regulating MMP secretion
[25]. Caspase 8 activity was increased at 30 minutes by
CoMTb and was returned to baseline by the caspase 8
inhibitor z-IETD-fmk (Figure 6A). Cells were then pre-
incubated with the caspase 8 inhibitor and stimulated
with CoMTb after two hours. A dose-dependent
increase in MMP-2 secretion was observed with increas-
ing concentrations of caspase 8 inhibitor, with MMP-2
secretion returned to basal levels after pre-treatment of
cultures with 1 μM z-IETD-fmk (Figure 6B, P < 0.01).
Next, we investigated the influence of the caspase 8
pathway on p38 MAPK. Caspase 8 inhibition led to a
paradoxical increase in p38 phosphorylation at 30 min-
utes (Figure 6C). There were no differences in cell num-
bers during these experiments. Finally, we investigated
whether caspase 8 might act via the NFB pathway.
Both p50 and p65 NFB subunits were up-regulated in
nuclear extracts from CoMTb-stimulated microglial
cells by 30 minutes. However, caspase 8 acts indepen-
dently of p65/p50 NF-kB nuclear translocation (Figure
6D).
Discussion
In this study, we demonstrated that a TNF-dependent
cytokine network involving M.tb-infected monocytes,
but not direct infection by M.tb, down-regulates MMP-
2 secretion from microglial cells via p38 MAP kinase,
NFB and caspase 8 pathways. Since M.tb infection and
TNF-a usually drive gene expression and secretion of
other MMPs, such as MMP-1, -3 and -9, leading to pro-
inflammatory damage this was an unexpected, paradoxi-
cal finding [33,37,42]. Specifically this was the only
down-regulated molecule when studying all MMPs in
this model system in our previously published work and
in particular contrast to the other gelatinase MMP-9
[33]. p38 staining has never previously been demon-
strated in vivo in human microglia. Caspase 8 has not
been implicated in the regulation of MMP secretion in
TB.
In our simplified cellular model of CNS TB, MMP-2
secretion was suppressed up to 96 hours by CoMTb
more profoundly than by M.tb alone. The effect of
monocyte-microglial networks was specific since neither
astrocyte nor microglial-derived conditioned medium
affected MMP-2 secretion. These data, albeit from a cell
line, are consistent with observations that MMP-2 was
not detected in parenchymal cells in CNS TB suggesting
that cell specific down-regulation may be occurring in
vivo [31,32]. Control of MMP-2 activity is usually
achieved by restricting the activation of the secreted
pro-enzyme [18]. However, in microglial cells decreased
MMP-2 secretion was mainly due to inhibition of
MMP-2 mRNA accumulation, a phenomenon only pre-
viously reported in astrocytoma cells [43]. It is possible
that this finding is specific to the CNS immune
response.
TNF-a was necessary, but not sufficient for MMP-2
suppression as 50 times the concentration of recombi-
nant molecule was needed to give the equivalent
CoMTb effect. We and others have previously
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Figure 3 p38 phosphorylation acts as the break for CoMTb
suppression of MMP-2 secretion. Microglial cells were incubated
with SB203580 or PD98059 for 2 h, and then stimulated with
CoMTb. MMP-2 secretion was analyzed at 72 h by Luminex and
gelatin zymography (representative gel shown). p38 inhibition
reverses CoMTb suppression and leads to supra-maximal MMP-2
secretion but ERK inhibition further suppresses secretion. Bars
represent mean values ± SD of three samples, representative of at
least duplicate experiments performed in triplicate. Data were
analyzed by one-way analysis of variance, followed by Tukey’s
multiple comparison. **p < 0.01.
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demonstrated that TNF-a is often a critical up-regulator
of MMP expression and secretion both in TB and other
model systems [13,25,40]. However, TNF-a has been
reported to down-regulate expression and secretion of
MMP-2 from both astrocytoma and choroid plexus
epithelial cells [43,44]. In contrast IL-1b had no effect
on MMP-2 secretion although in our previous work we
demonstrated that this cytokine drives astrocyte MMP-9
secretion [45]. Dexamethasone tends to down-regulate
proinflammatory responses and has a clinically impor-
tant adjuvant role in decreasing inflammation in the
treatment of CNS TB [46]. Dexamethasone did not
reverse the paradoxical effect of CoMTb on MMP-2
gene expression. Similarly in a rat meningitis model
dexamethasone did not influence parenchymal MMP-2
expression suggesting the MMP-2 gene may not be ster-
oid responsive in the CNS [47].
We investigated the role of ERK and p38 MAP kinase
pathways in MMP-2 down-regulation. ERK inhibition
further inhibited MMP-2 secretion. In contrast p38
MAP kinase acts as a brake to MMP-2 secretion as pre-
incubation of cells with the specific p38 inhibitor
SB203580 leading to supra-maximal secretion of MMP-
2. The p38 MAP kinase pathway is a critical regulator
of inflammatory processes [22]. Our group has demon-
strated that p38 acts as a brake in a similar way in pul-
monary epithelial cells [40]. To strengthen these in vitro
findings, we investigated the expression of phospho-p38
A B
C D
E F
Figure 4 Microglia are likely to express phosphorylated p38 in patients with CNS TB. Brain biopsies from five patients with CNS TB were
stained. (A) H&E stained section of cerebellar cortex shows typical TB necrotizing granulomas (original magnification 10×). (B) Iba1 (a microglial/
macrophage marker) staining confirms a florid microglial and macrophage infiltrate in the TB granuloma (original magnification 20×). (C) p38
immunoreactivity is almost exclusively expressed in the nucleus of microglial cells (original magnification 40×). (D) Iba-1 staining in microglia
denoted by arrows with rectangle denoting area enlarged for (E) (original magnification 20×) (E) corresponding p38 positive microglia with
characteristic nuclear shape enlarged from rectangle in (D) (original magnification 40×). For immunostaining (B - E) areas of immunoreactivity
appear as brown against the blue counterstain. (F) Omission of the primary antibody in CNS TB biopsy demonstrates no immunoreactivity
(original magnification 20×).
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Figure 5 CoMTb suppression of MMP-2 secretion is mediated
by the NFB pathway. (A), Cells were preincubated with helenalin
for 2 h and then stimulated with CoMTb. 72 h cell culture
supernatants were analyzed by Luminex, confirmed by gelatin
zymography (representative zymogram shown). (B), SC-514
inhibition. Bars represent mean values ± SD of three samples,
representative of at least duplicate experiments performed in
triplicate. Data were analyzed by one-way analysis of variance,
followed by Tukey’s multiple comparison. **p < 0.01.
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Figure 6 Caspase 8 mediates CoMTb induced MMP-2
suppression. (A) Caspase 8 activity is up-regulated by CoMTb at 30
minutes and returned to baseline by the inhibitor z-IETD-fmk.
Representative Western blot shown. (B) Caspase 8 inhibition restores
CoMTb-mediated MMP-2 suppression. 72 h supernatants were
analyzed by Luminex and confirmed by gelatin zymography. Bars
represent mean values ± SD of three samples, representative of at
least duplicate experiments performed in triplicate. Data were
analyzed by one-way analysis of variance, followed by Tukey’s
multiple comparison. **p < 0.01. (C) Phospho-p38 activity at 30
minutes is up-regulated by caspase 8 inhibition. Representative
Western blot shown. Total p38 blot to show equal lane loading. (D)
Caspase 8 inhibition does not alter NFB nuclear dynamics. Nuclear
extracts of CoM stimulated cells were taken at 30 mins and p50 &
p65 subunits measured by ELISA.
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in biopsies from proven human CNS TB patients and
showed likely parenchymal activation of this pathway in
microglia in vivo for the first time, an important finding
from this work. It is not possible using any currently
available markers to be certain whether these positive
cells were resident microglia or infiltrating peripheral
macrophages [48].
Blockade of the NFB pathway with SC-514 restored
CoMTb inhibited MMP-2 secretion to supra-maximal
levels. Similarly, helenalin opposed the effect of CoMTb
on MMP-2. Down-regulation of gene expression by the
NFB pathway has been previously described in other
secretory pathways, such as apolipoprotein E mRNA in
adipocytes via p50 homodimer binding to the promoter,
but this is the first time that control of MMP-2 secretion
has been shown to be modulated in this way in the CNS
[49,50]. In contrast many other MMP genes are known
to have NFB responsive elements in their promoters
that act as up-regulators of gene transcription [51,52].
Importantly we showed, for the first time, that caspase
8 inhibition restored CoMTb-induced MMP-2 secretion
in human microglial cells in a dose dependent fashion
independent of the p38 and NFB pathways. Although
p38 signaling was reported as essential for caspase-
induced apoptosis in macrophages, we were unable to
demonstrate p38 driven caspase 8 activation in our sys-
tem and blockade did not alter cell numbers [53]. Non-
apoptotic roles for caspase 8 including NFB activation
have been described but here caspase 8 blockade had no
effect on nuclear recruitment of p50 and p65 NFB sub-
units [54]. In contrast caspase 8 may mediate TNF-a
activation of NFB via a p38 independent pathway
involving FLICE-associated huge protein (FLASH)-cas-
pase 8 complexes in HeLa and HEK293 cells [55]. Cas-
pase-2 cleavage is also downstream of TNF-a receptor
activation and has demonstrated non-apoptotic roles
including cell matrix adhesion, as do caspase 3 and 7
[56,57]. Finally, although caspase 8 activity was demon-
strated to be rapidly induced by CoMTb, the effect on
MMP-2 secretion was more delayed which suggest that
it is probable that there are additional intermediary
events occurring in this pathway which are not yet
characterized.
In summary, there is a decrease in microglial MMP-2
secretion in response to networks driven by M.tb-
infected monocytes, which coupled with the known rise
in the acknowledged effector molecule MMP-9 is likely
to lead to a change in the CNS inflammatory milieu
characterized by alterations in chemokine and cytokine
processing as well as cellular migration [58]. Unexpect-
edly, such networks are paradoxically dependent upon
the pro-inflammatory cytokine TNF-a (but not IL-1b).
Within microglia, the p38 MAP kinase, NFB p65 subu-
nits and caspase 8 pathways are all involved in the
control of MMP-2 down-regulation. Caspase 8, which to
date has been more implicated in regulation of apoptosis
in infected cells, acts independently from a separate p38
MAP kinase/NFB axis to suppress MMP-2 secretion in
microglial cells in this simplified cellular model of CNS
TB.
Additional material
Additional file 1: Figure S1. (A) CoMTb suppression of MMP-2 secretion
is not mediated by IL-1b and TNF-a synergy. Microglia were stimulated
with TNF-a and IL-1b either alone or in combination. There was no
additional effect of adding IL-1b to TNF-a. (B) CoMTb suppression of
MMP-2 secretion is not mediated by M.tb antigens and TNF-a synergy.
Microglia were stimulated with TNF-a 100 ng/ml, Tb medium (Tb med
4.7 μl/ml), either alone or in combination. No effect was seen on MMP-2
secretion. 72 h supernatants were analyzed by Luminex. Bars represent
mean values ± SD of three samples, representative of at least duplicate
experiments performed in triplicate. Data were analyzed by one-way
analysis of variance, followed by Tukey’s multiple comparison. **p < 0.01.
Additional file 2: Figure S2. Dexamethasone does not reverse CoMTb
induced suppression of MMP-2 secretion. Cells were preincubated with
dexamethasone for 2 hours then stimulated with CoMTb. 72 h
supernatants were analyzed by Luminex and confirmed by gelatin
zymography. Bars represent mean values ± SD of three samples,
representative of at least duplicate experiments performed in triplicate.
Data were analyzed by one-way analysis of variance, followed by Tukey’s
multiple comparison. **p < 0.01.
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